nodes	percent_of_prediction	percent_of_DWPC	metapath
Doxepin—CYP2C19—prostate cancer	0.119	0.611	CbGaD
Doxepin—CYP3A4—prostate cancer	0.0755	0.389	CbGaD
Doxepin—ORM1—Abiraterone—prostate cancer	0.0619	0.143	CbGbCtD
Doxepin—CYP2C19—Bicalutamide—prostate cancer	0.0204	0.0471	CbGbCtD
Doxepin—CYP2C19—Nilutamide—prostate cancer	0.0204	0.0471	CbGbCtD
Doxepin—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0188	0.0433	CbGbCtD
Doxepin—CYP2C9—Nilutamide—prostate cancer	0.0169	0.0391	CbGbCtD
Doxepin—CYP2C9—Bicalutamide—prostate cancer	0.0169	0.0391	CbGbCtD
Doxepin—CYP2C19—Flutamide—prostate cancer	0.0169	0.039	CbGbCtD
Doxepin—CYP1A2—Flutamide—prostate cancer	0.0156	0.036	CbGbCtD
Doxepin—CYP2D6—Bicalutamide—prostate cancer	0.0155	0.0358	CbGbCtD
Doxepin—ABCB1—Estramustine—prostate cancer	0.0153	0.0353	CbGbCtD
Doxepin—ADRA1B—vas deferens—prostate cancer	0.0132	0.238	CbGeAlD
Doxepin—CYP2D6—Abiraterone—prostate cancer	0.0128	0.0297	CbGbCtD
Doxepin—CYP1A2—Estrone—prostate cancer	0.0113	0.026	CbGbCtD
Doxepin—CYP2C9—Estrone—prostate cancer	0.0101	0.0235	CbGbCtD
Doxepin—ABCB1—Cabazitaxel—prostate cancer	0.0101	0.0233	CbGbCtD
Doxepin—CYP3A4—Bicalutamide—prostate cancer	0.00985	0.0228	CbGbCtD
Doxepin—ABCB1—Estrone—prostate cancer	0.00985	0.0228	CbGbCtD
Doxepin—CYP3A4—Estramustine—prostate cancer	0.00916	0.0212	CbGbCtD
Doxepin—ABCB1—Ethinyl Estradiol—prostate cancer	0.00878	0.0203	CbGbCtD
Doxepin—CYP3A4—Abiraterone—prostate cancer	0.00816	0.0189	CbGbCtD
Doxepin—CYP3A4—Flutamide—prostate cancer	0.00816	0.0189	CbGbCtD
Doxepin—CYP2C9—Capecitabine—prostate cancer	0.00769	0.0178	CbGbCtD
Doxepin—CYP1A2—Conjugated Estrogens—prostate cancer	0.00737	0.017	CbGbCtD
Doxepin—CYP2C19—Estradiol—prostate cancer	0.00701	0.0162	CbGbCtD
Doxepin—CYP1A2—Estradiol—prostate cancer	0.00647	0.0149	CbGbCtD
Doxepin—ABCB1—Conjugated Estrogens—prostate cancer	0.00644	0.0149	CbGbCtD
Doxepin—CHRM3—ureter—prostate cancer	0.00619	0.111	CbGeAlD
Doxepin—CYP3A4—Cabazitaxel—prostate cancer	0.00604	0.014	CbGbCtD
Doxepin—CYP2C19—Prednisone—prostate cancer	0.00603	0.0139	CbGbCtD
Doxepin—CYP3A4—Estrone—prostate cancer	0.0059	0.0136	CbGbCtD
Doxepin—ABCB1—Mitoxantrone—prostate cancer	0.00586	0.0135	CbGbCtD
Doxepin—CYP2C9—Estradiol—prostate cancer	0.00583	0.0135	CbGbCtD
Doxepin—ABCB1—Estradiol—prostate cancer	0.00566	0.0131	CbGbCtD
Doxepin—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00526	0.0122	CbGbCtD
Doxepin—ABCB1—Prednisone—prostate cancer	0.00486	0.0112	CbGbCtD
Doxepin—CYP1A2—Etoposide—prostate cancer	0.00422	0.00976	CbGbCtD
Doxepin—CYP3A4—Conjugated Estrogens—prostate cancer	0.00386	0.00892	CbGbCtD
Doxepin—ABCB1—Etoposide—prostate cancer	0.00369	0.00853	CbGbCtD
Doxepin—CYP3A4—Mitoxantrone—prostate cancer	0.00351	0.00811	CbGbCtD
Doxepin—CYP3A4—Estradiol—prostate cancer	0.00339	0.00783	CbGbCtD
Doxepin—ABCB1—Docetaxel—prostate cancer	0.00338	0.00781	CbGbCtD
Doxepin—CYP3A4—Prednisone—prostate cancer	0.00291	0.00673	CbGbCtD
Doxepin—ABCB1—Doxorubicin—prostate cancer	0.00252	0.00582	CbGbCtD
Doxepin—CYP2D6—Doxorubicin—prostate cancer	0.00237	0.00549	CbGbCtD
Doxepin—CYP3A4—Etoposide—prostate cancer	0.00221	0.00511	CbGbCtD
Doxepin—CYP3A4—Docetaxel—prostate cancer	0.00202	0.00468	CbGbCtD
Doxepin—CYP2C19—urine—prostate cancer	0.00187	0.0336	CbGeAlD
Doxepin—HRH4—bone marrow—prostate cancer	0.00166	0.0298	CbGeAlD
Doxepin—CYP1A2—urine—prostate cancer	0.00153	0.0275	CbGeAlD
Doxepin—CYP3A4—Doxorubicin—prostate cancer	0.00151	0.00349	CbGbCtD
Doxepin—CYP2C9—urine—prostate cancer	0.00145	0.0261	CbGeAlD
Doxepin—HTR2A—urine—prostate cancer	0.00119	0.0215	CbGeAlD
Doxepin—ADRA1D—prostate gland—prostate cancer	0.00115	0.0208	CbGeAlD
Doxepin—CYP3A4—urine—prostate cancer	0.00111	0.0199	CbGeAlD
Doxepin—CYP2D6—urine—prostate cancer	0.00109	0.0196	CbGeAlD
Doxepin—ORM1—prostate gland—prostate cancer	0.000951	0.0171	CbGeAlD
Doxepin—CHRM5—epithelium—prostate cancer	0.000949	0.0171	CbGeAlD
Doxepin—CHRM2—prostate gland—prostate cancer	0.000887	0.0159	CbGeAlD
Doxepin—ADRA1D—epithelium—prostate cancer	0.000849	0.0153	CbGeAlD
Doxepin—CHRM1—prostate gland—prostate cancer	0.000807	0.0145	CbGeAlD
Doxepin—ADRA1B—renal system—prostate cancer	0.000805	0.0145	CbGeAlD
Doxepin—ADRA1D—urethra—prostate cancer	0.000773	0.0139	CbGeAlD
Doxepin—CHRM4—testis—prostate cancer	0.000728	0.0131	CbGeAlD
Doxepin—CHRM3—prostate gland—prostate cancer	0.000722	0.013	CbGeAlD
Doxepin—ADRA1A—prostate gland—prostate cancer	0.000663	0.0119	CbGeAlD
Doxepin—KCNH2—prostate gland—prostate cancer	0.000641	0.0115	CbGeAlD
Doxepin—ADRA2C—prostate gland—prostate cancer	0.000632	0.0114	CbGeAlD
Doxepin—KCNH2—seminal vesicle—prostate cancer	0.000542	0.00974	CbGeAlD
Doxepin—ADRA2C—seminal vesicle—prostate cancer	0.000535	0.00961	CbGeAlD
Doxepin—HRH1—prostate gland—prostate cancer	0.000513	0.00923	CbGeAlD
Doxepin—ADRA2A—prostate gland—prostate cancer	0.000504	0.00907	CbGeAlD
Doxepin—CHRM3—renal system—prostate cancer	0.000492	0.00885	CbGeAlD
Doxepin—HTR1A—renal system—prostate cancer	0.00049	0.00882	CbGeAlD
Doxepin—ORM1—bone marrow—prostate cancer	0.00049	0.00881	CbGeAlD
Doxepin—ADRA1A—epithelium—prostate cancer	0.000487	0.00876	CbGeAlD
Doxepin—CHRM3—urethra—prostate cancer	0.000484	0.0087	CbGeAlD
Doxepin—ADRA1A—renal system—prostate cancer	0.000452	0.00813	CbGeAlD
Doxepin—KCNH2—renal system—prostate cancer	0.000437	0.00785	CbGeAlD
Doxepin—Dimetacrine—ACHE—prostate cancer	0.000434	0.126	CrCbGaD
Doxepin—HRH2—lymph node—prostate cancer	0.000432	0.00776	CbGeAlD
Doxepin—ADRA2C—renal system—prostate cancer	0.000431	0.00774	CbGeAlD
Doxepin—KCNH2—urethra—prostate cancer	0.000429	0.00771	CbGeAlD
Doxepin—ADRA2A—seminal vesicle—prostate cancer	0.000427	0.00767	CbGeAlD
Doxepin—ADRA2C—urethra—prostate cancer	0.000423	0.00761	CbGeAlD
Doxepin—HRH1—epithelium—prostate cancer	0.000377	0.00678	CbGeAlD
Doxepin—CYP1A2—renal system—prostate cancer	0.000374	0.00672	CbGeAlD
Doxepin—HRH1—urethra—prostate cancer	0.000344	0.00618	CbGeAlD
Doxepin—ADRA2A—urethra—prostate cancer	0.000338	0.00607	CbGeAlD
Doxepin—KCNH2—bone marrow—prostate cancer	0.00033	0.00593	CbGeAlD
Doxepin—CHRM3—testis—prostate cancer	0.000318	0.00572	CbGeAlD
Doxepin—HTR2A—epithelium—prostate cancer	0.000315	0.00566	CbGeAlD
Doxepin—SLC6A2—testis—prostate cancer	0.000314	0.00565	CbGeAlD
Doxepin—ORM1—lymph node—prostate cancer	0.000304	0.00546	CbGeAlD
Doxepin—HTR2A—renal system—prostate cancer	0.000292	0.00525	CbGeAlD
Doxepin—DRD2—testis—prostate cancer	0.000286	0.00515	CbGeAlD
Doxepin—KCNH2—testis—prostate cancer	0.000282	0.00507	CbGeAlD
Doxepin—ABCB1—prostate gland—prostate cancer	0.000281	0.00505	CbGeAlD
Doxepin—ADRA2C—testis—prostate cancer	0.000278	0.00501	CbGeAlD
Doxepin—CYP3A4—renal system—prostate cancer	0.000271	0.00486	CbGeAlD
Doxepin—CYP2D6—renal system—prostate cancer	0.000266	0.00479	CbGeAlD
Doxepin—HTR2B—lymph node—prostate cancer	0.000256	0.00461	CbGeAlD
Doxepin—ABCB1—seminal vesicle—prostate cancer	0.000238	0.00427	CbGeAlD
Doxepin—SLC6A2—lymph node—prostate cancer	0.000228	0.0041	CbGeAlD
Doxepin—HRH1—testis—prostate cancer	0.000226	0.00407	CbGeAlD
Doxepin—ADRA2A—testis—prostate cancer	0.000222	0.00399	CbGeAlD
Doxepin—ABCB1—epithelium—prostate cancer	0.000206	0.00371	CbGeAlD
Doxepin—KCNH2—lymph node—prostate cancer	0.000205	0.00368	CbGeAlD
Doxepin—ADRA2C—lymph node—prostate cancer	0.000202	0.00363	CbGeAlD
Doxepin—ABCB1—renal system—prostate cancer	0.000192	0.00344	CbGeAlD
Doxepin—HTR2A—testis—prostate cancer	0.000189	0.0034	CbGeAlD
Doxepin—ABCB1—urethra—prostate cancer	0.000188	0.00338	CbGeAlD
Doxepin—CYP2D6—testis—prostate cancer	0.000172	0.00309	CbGeAlD
Doxepin—Oxcarbazepine—CYP3A5—prostate cancer	0.000166	0.0479	CrCbGaD
Doxepin—HRH1—lymph node—prostate cancer	0.000164	0.00295	CbGeAlD
Doxepin—ADRA2A—lymph node—prostate cancer	0.000161	0.0029	CbGeAlD
Doxepin—Thiothixene—SLC22A1—prostate cancer	0.000149	0.0432	CrCbGaD
Doxepin—ABCB1—bone marrow—prostate cancer	0.000145	0.0026	CbGeAlD
Doxepin—Desipramine—SLC22A3—prostate cancer	0.000132	0.0383	CrCbGaD
Doxepin—Diphenhydramine—CYP2C18—prostate cancer	0.00013	0.0378	CrCbGaD
Doxepin—Clomipramine—GSTP1—prostate cancer	0.000127	0.0369	CrCbGaD
Doxepin—ABCB1—testis—prostate cancer	0.000124	0.00223	CbGeAlD
Doxepin—Desipramine—CYP2C18—prostate cancer	0.000116	0.0336	CrCbGaD
Doxepin—Oxcarbazepine—CYP2C19—prostate cancer	0.000113	0.0326	CrCbGaD
Doxepin—Imipramine—SLC22A3—prostate cancer	0.000112	0.0325	CrCbGaD
Doxepin—Diphenhydramine—SLC22A1—prostate cancer	0.000106	0.0308	CrCbGaD
Doxepin—Imipramine—CYP2C18—prostate cancer	9.85e-05	0.0285	CrCbGaD
Doxepin—Desipramine—SLC22A1—prostate cancer	9.48e-05	0.0275	CrCbGaD
Doxepin—Olopatadine—CYP3A4—prostate cancer	9.32e-05	0.027	CrCbGaD
Doxepin—Nortriptyline—CYP3A5—prostate cancer	9.29e-05	0.0269	CrCbGaD
Doxepin—ABCB1—lymph node—prostate cancer	8.97e-05	0.00161	CbGeAlD
Doxepin—Alimemazine—CYP3A4—prostate cancer	8.5e-05	0.0246	CrCbGaD
Doxepin—Imipramine—SLC22A1—prostate cancer	8.04e-05	0.0233	CrCbGaD
Doxepin—Cyclobenzaprine—CYP3A4—prostate cancer	7.83e-05	0.0227	CrCbGaD
Doxepin—Desipramine—CYP2A6—prostate cancer	7.4e-05	0.0214	CrCbGaD
Doxepin—Oxcarbazepine—CYP3A4—prostate cancer	7.16e-05	0.0207	CrCbGaD
Doxepin—Clomipramine—CYP2C19—prostate cancer	6.47e-05	0.0187	CrCbGaD
Doxepin—Amitriptyline—CYP3A5—prostate cancer	6.45e-05	0.0187	CrCbGaD
Doxepin—Nortriptyline—CYP2E1—prostate cancer	6.38e-05	0.0185	CrCbGaD
Doxepin—Nortriptyline—CYP2C19—prostate cancer	6.32e-05	0.0183	CrCbGaD
Doxepin—Desipramine—ADRB2—prostate cancer	6.05e-05	0.0175	CrCbGaD
Doxepin—Trimipramine—CYP2C19—prostate cancer	5.95e-05	0.0172	CrCbGaD
Doxepin—Diphenhydramine—CYP2C19—prostate cancer	5.85e-05	0.0169	CrCbGaD
Doxepin—Orphenadrine—CYP2E1—prostate cancer	5.58e-05	0.0162	CrCbGaD
Doxepin—Desipramine—CYP2E1—prostate cancer	5.26e-05	0.0152	CrCbGaD
Doxepin—Desipramine—CYP2C19—prostate cancer	5.21e-05	0.0151	CrCbGaD
Doxepin—Promazine—CYP2C19—prostate cancer	5.04e-05	0.0146	CrCbGaD
Doxepin—Imipramine—CYP2E1—prostate cancer	4.46e-05	0.0129	CrCbGaD
Doxepin—Amitriptyline—CYP2E1—prostate cancer	4.43e-05	0.0128	CrCbGaD
Doxepin—Imipramine—CYP2C19—prostate cancer	4.41e-05	0.0128	CrCbGaD
Doxepin—Amitriptyline—CYP2C19—prostate cancer	4.39e-05	0.0127	CrCbGaD
Doxepin—Clomipramine—CYP3A4—prostate cancer	4.11e-05	0.0119	CrCbGaD
Doxepin—Nortriptyline—CYP3A4—prostate cancer	4.02e-05	0.0116	CrCbGaD
Doxepin—Trimipramine—CYP3A4—prostate cancer	3.79e-05	0.011	CrCbGaD
Doxepin—Orphenadrine—CYP3A4—prostate cancer	3.52e-05	0.0102	CrCbGaD
Doxepin—Bradycardia—Doxorubicin—prostate cancer	3.43e-05	0.000174	CcSEcCtD
Doxepin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	3.43e-05	0.000174	CcSEcCtD
Doxepin—Dyspnoea—Docetaxel—prostate cancer	3.42e-05	0.000174	CcSEcCtD
Doxepin—Somnolence—Docetaxel—prostate cancer	3.41e-05	0.000173	CcSEcCtD
Doxepin—Discomfort—Prednisone—prostate cancer	3.41e-05	0.000173	CcSEcCtD
Doxepin—Eye disorder—Epirubicin—prostate cancer	3.4e-05	0.000173	CcSEcCtD
Doxepin—Hypersensitivity—Etoposide—prostate cancer	3.4e-05	0.000173	CcSEcCtD
Doxepin—Tinnitus—Epirubicin—prostate cancer	3.4e-05	0.000173	CcSEcCtD
Doxepin—Musculoskeletal discomfort—Capecitabine—prostate cancer	3.38e-05	0.000172	CcSEcCtD
Doxepin—Flushing—Epirubicin—prostate cancer	3.38e-05	0.000172	CcSEcCtD
Doxepin—Cardiac disorder—Epirubicin—prostate cancer	3.38e-05	0.000172	CcSEcCtD
Doxepin—Dyspepsia—Docetaxel—prostate cancer	3.38e-05	0.000172	CcSEcCtD
Doxepin—Hepatitis—Doxorubicin—prostate cancer	3.37e-05	0.000171	CcSEcCtD
Doxepin—Insomnia—Capecitabine—prostate cancer	3.36e-05	0.000171	CcSEcCtD
Doxepin—Hypoaesthesia—Doxorubicin—prostate cancer	3.35e-05	0.000171	CcSEcCtD
Doxepin—Pharyngitis—Doxorubicin—prostate cancer	3.34e-05	0.00017	CcSEcCtD
Doxepin—Paraesthesia—Capecitabine—prostate cancer	3.34e-05	0.00017	CcSEcCtD
Doxepin—Decreased appetite—Docetaxel—prostate cancer	3.33e-05	0.00017	CcSEcCtD
Doxepin—Urinary tract disorder—Doxorubicin—prostate cancer	3.33e-05	0.000169	CcSEcCtD
Doxepin—Oedema peripheral—Doxorubicin—prostate cancer	3.32e-05	0.000169	CcSEcCtD
Doxepin—Gastrointestinal disorder—Docetaxel—prostate cancer	3.31e-05	0.000168	CcSEcCtD
Doxepin—Asthenia—Etoposide—prostate cancer	3.31e-05	0.000168	CcSEcCtD
Doxepin—Connective tissue disorder—Doxorubicin—prostate cancer	3.31e-05	0.000168	CcSEcCtD
Doxepin—Dyspnoea—Capecitabine—prostate cancer	3.31e-05	0.000168	CcSEcCtD
Doxepin—Desipramine—CYP3A4—prostate cancer	3.31e-05	0.00959	CrCbGaD
Doxepin—Oedema—Prednisone—prostate cancer	3.31e-05	0.000168	CcSEcCtD
Doxepin—Fatigue—Docetaxel—prostate cancer	3.31e-05	0.000168	CcSEcCtD
Doxepin—Angiopathy—Epirubicin—prostate cancer	3.3e-05	0.000168	CcSEcCtD
Doxepin—Urethral disorder—Doxorubicin—prostate cancer	3.3e-05	0.000168	CcSEcCtD
Doxepin—Nausea—Mitoxantrone—prostate cancer	3.3e-05	0.000168	CcSEcCtD
Doxepin—Immune system disorder—Epirubicin—prostate cancer	3.29e-05	0.000167	CcSEcCtD
Doxepin—Infection—Prednisone—prostate cancer	3.29e-05	0.000167	CcSEcCtD
Doxepin—Mediastinal disorder—Epirubicin—prostate cancer	3.28e-05	0.000167	CcSEcCtD
Doxepin—Pain—Docetaxel—prostate cancer	3.28e-05	0.000167	CcSEcCtD
Doxepin—Constipation—Docetaxel—prostate cancer	3.28e-05	0.000167	CcSEcCtD
Doxepin—Dyspepsia—Capecitabine—prostate cancer	3.27e-05	0.000166	CcSEcCtD
Doxepin—Chills—Epirubicin—prostate cancer	3.27e-05	0.000166	CcSEcCtD
Doxepin—Pruritus—Etoposide—prostate cancer	3.27e-05	0.000166	CcSEcCtD
Doxepin—Shock—Prednisone—prostate cancer	3.26e-05	0.000166	CcSEcCtD
Doxepin—Arrhythmia—Epirubicin—prostate cancer	3.25e-05	0.000165	CcSEcCtD
Doxepin—Nervous system disorder—Prednisone—prostate cancer	3.24e-05	0.000165	CcSEcCtD
Doxepin—Tachycardia—Prednisone—prostate cancer	3.23e-05	0.000164	CcSEcCtD
Doxepin—Decreased appetite—Capecitabine—prostate cancer	3.23e-05	0.000164	CcSEcCtD
Doxepin—Alopecia—Epirubicin—prostate cancer	3.22e-05	0.000164	CcSEcCtD
Doxepin—Skin disorder—Prednisone—prostate cancer	3.21e-05	0.000163	CcSEcCtD
Doxepin—Gastrointestinal disorder—Capecitabine—prostate cancer	3.21e-05	0.000163	CcSEcCtD
Doxepin—Promazine—CYP3A4—prostate cancer	3.21e-05	0.00929	CrCbGaD
Doxepin—Fatigue—Capecitabine—prostate cancer	3.2e-05	0.000163	CcSEcCtD
Doxepin—Hyperhidrosis—Prednisone—prostate cancer	3.2e-05	0.000163	CcSEcCtD
Doxepin—Mental disorder—Epirubicin—prostate cancer	3.19e-05	0.000162	CcSEcCtD
Doxepin—Pain—Capecitabine—prostate cancer	3.18e-05	0.000162	CcSEcCtD
Doxepin—Constipation—Capecitabine—prostate cancer	3.18e-05	0.000162	CcSEcCtD
Doxepin—Malnutrition—Epirubicin—prostate cancer	3.17e-05	0.000161	CcSEcCtD
Doxepin—Erythema—Epirubicin—prostate cancer	3.17e-05	0.000161	CcSEcCtD
Doxepin—Feeling abnormal—Docetaxel—prostate cancer	3.16e-05	0.000161	CcSEcCtD
Doxepin—Diarrhoea—Etoposide—prostate cancer	3.16e-05	0.000161	CcSEcCtD
Doxepin—Anorexia—Prednisone—prostate cancer	3.15e-05	0.00016	CcSEcCtD
Doxepin—Eye disorder—Doxorubicin—prostate cancer	3.15e-05	0.00016	CcSEcCtD
Doxepin—Tinnitus—Doxorubicin—prostate cancer	3.14e-05	0.00016	CcSEcCtD
Doxepin—Gastrointestinal pain—Docetaxel—prostate cancer	3.14e-05	0.00016	CcSEcCtD
Doxepin—Flushing—Doxorubicin—prostate cancer	3.13e-05	0.000159	CcSEcCtD
Doxepin—Cardiac disorder—Doxorubicin—prostate cancer	3.13e-05	0.000159	CcSEcCtD
Doxepin—Flatulence—Epirubicin—prostate cancer	3.12e-05	0.000159	CcSEcCtD
Doxepin—Tension—Epirubicin—prostate cancer	3.11e-05	0.000158	CcSEcCtD
Doxepin—Dysgeusia—Epirubicin—prostate cancer	3.1e-05	0.000158	CcSEcCtD
Doxepin—Nervousness—Epirubicin—prostate cancer	3.08e-05	0.000157	CcSEcCtD
Doxepin—Back pain—Epirubicin—prostate cancer	3.07e-05	0.000156	CcSEcCtD
Doxepin—Feeling abnormal—Capecitabine—prostate cancer	3.06e-05	0.000156	CcSEcCtD
Doxepin—Angiopathy—Doxorubicin—prostate cancer	3.06e-05	0.000155	CcSEcCtD
Doxepin—Dizziness—Etoposide—prostate cancer	3.05e-05	0.000155	CcSEcCtD
Doxepin—Muscle spasms—Epirubicin—prostate cancer	3.05e-05	0.000155	CcSEcCtD
Doxepin—Immune system disorder—Doxorubicin—prostate cancer	3.04e-05	0.000155	CcSEcCtD
Doxepin—Gastrointestinal pain—Capecitabine—prostate cancer	3.04e-05	0.000154	CcSEcCtD
Doxepin—Mediastinal disorder—Doxorubicin—prostate cancer	3.04e-05	0.000154	CcSEcCtD
Doxepin—Abdominal pain—Docetaxel—prostate cancer	3.03e-05	0.000154	CcSEcCtD
Doxepin—Body temperature increased—Docetaxel—prostate cancer	3.03e-05	0.000154	CcSEcCtD
Doxepin—Chills—Doxorubicin—prostate cancer	3.02e-05	0.000154	CcSEcCtD
Doxepin—Musculoskeletal discomfort—Prednisone—prostate cancer	3.01e-05	0.000153	CcSEcCtD
Doxepin—Arrhythmia—Doxorubicin—prostate cancer	3.01e-05	0.000153	CcSEcCtD
Doxepin—Insomnia—Prednisone—prostate cancer	2.99e-05	0.000152	CcSEcCtD
Doxepin—Vision blurred—Epirubicin—prostate cancer	2.99e-05	0.000152	CcSEcCtD
Doxepin—Alopecia—Doxorubicin—prostate cancer	2.98e-05	0.000151	CcSEcCtD
Doxepin—Paraesthesia—Prednisone—prostate cancer	2.97e-05	0.000151	CcSEcCtD
Doxepin—Mental disorder—Doxorubicin—prostate cancer	2.95e-05	0.00015	CcSEcCtD
Doxepin—Urticaria—Capecitabine—prostate cancer	2.95e-05	0.00015	CcSEcCtD
Doxepin—Ill-defined disorder—Epirubicin—prostate cancer	2.94e-05	0.00015	CcSEcCtD
Doxepin—Abdominal pain—Capecitabine—prostate cancer	2.94e-05	0.000149	CcSEcCtD
Doxepin—Body temperature increased—Capecitabine—prostate cancer	2.94e-05	0.000149	CcSEcCtD
Doxepin—Vomiting—Etoposide—prostate cancer	2.94e-05	0.000149	CcSEcCtD
Doxepin—Malnutrition—Doxorubicin—prostate cancer	2.93e-05	0.000149	CcSEcCtD
Doxepin—Erythema—Doxorubicin—prostate cancer	2.93e-05	0.000149	CcSEcCtD
Doxepin—Anaemia—Epirubicin—prostate cancer	2.93e-05	0.000149	CcSEcCtD
Doxepin—Agitation—Epirubicin—prostate cancer	2.91e-05	0.000148	CcSEcCtD
Doxepin—Dyspepsia—Prednisone—prostate cancer	2.91e-05	0.000148	CcSEcCtD
Doxepin—Rash—Etoposide—prostate cancer	2.91e-05	0.000148	CcSEcCtD
Doxepin—Dermatitis—Etoposide—prostate cancer	2.91e-05	0.000148	CcSEcCtD
Doxepin—Headache—Etoposide—prostate cancer	2.89e-05	0.000147	CcSEcCtD
Doxepin—Flatulence—Doxorubicin—prostate cancer	2.89e-05	0.000147	CcSEcCtD
Doxepin—Tension—Doxorubicin—prostate cancer	2.88e-05	0.000146	CcSEcCtD
Doxepin—Decreased appetite—Prednisone—prostate cancer	2.88e-05	0.000146	CcSEcCtD
Doxepin—Dysgeusia—Doxorubicin—prostate cancer	2.87e-05	0.000146	CcSEcCtD
Doxepin—Malaise—Epirubicin—prostate cancer	2.86e-05	0.000145	CcSEcCtD
Doxepin—Fatigue—Prednisone—prostate cancer	2.85e-05	0.000145	CcSEcCtD
Doxepin—Nervousness—Doxorubicin—prostate cancer	2.85e-05	0.000145	CcSEcCtD
Doxepin—Vertigo—Epirubicin—prostate cancer	2.85e-05	0.000145	CcSEcCtD
Doxepin—Syncope—Epirubicin—prostate cancer	2.84e-05	0.000145	CcSEcCtD
Doxepin—Leukopenia—Epirubicin—prostate cancer	2.84e-05	0.000144	CcSEcCtD
Doxepin—Back pain—Doxorubicin—prostate cancer	2.84e-05	0.000144	CcSEcCtD
Doxepin—Constipation—Prednisone—prostate cancer	2.83e-05	0.000144	CcSEcCtD
Doxepin—Hypersensitivity—Docetaxel—prostate cancer	2.83e-05	0.000144	CcSEcCtD
Doxepin—Muscle spasms—Doxorubicin—prostate cancer	2.82e-05	0.000143	CcSEcCtD
Doxepin—Imipramine—CYP3A4—prostate cancer	2.81e-05	0.00813	CrCbGaD
Doxepin—Palpitations—Epirubicin—prostate cancer	2.8e-05	0.000142	CcSEcCtD
Doxepin—Amitriptyline—CYP3A4—prostate cancer	2.79e-05	0.00808	CrCbGaD
Doxepin—Loss of consciousness—Epirubicin—prostate cancer	2.79e-05	0.000142	CcSEcCtD
Doxepin—Cough—Epirubicin—prostate cancer	2.77e-05	0.000141	CcSEcCtD
Doxepin—Vision blurred—Doxorubicin—prostate cancer	2.76e-05	0.000141	CcSEcCtD
Doxepin—Asthenia—Docetaxel—prostate cancer	2.75e-05	0.00014	CcSEcCtD
Doxepin—Convulsion—Epirubicin—prostate cancer	2.75e-05	0.00014	CcSEcCtD
Doxepin—Nausea—Etoposide—prostate cancer	2.74e-05	0.000139	CcSEcCtD
Doxepin—Hypertension—Epirubicin—prostate cancer	2.74e-05	0.000139	CcSEcCtD
Doxepin—Hypersensitivity—Capecitabine—prostate cancer	2.74e-05	0.000139	CcSEcCtD
Doxepin—Feeling abnormal—Prednisone—prostate cancer	2.73e-05	0.000139	CcSEcCtD
Doxepin—Ill-defined disorder—Doxorubicin—prostate cancer	2.72e-05	0.000138	CcSEcCtD
Doxepin—Pruritus—Docetaxel—prostate cancer	2.71e-05	0.000138	CcSEcCtD
Doxepin—Anaemia—Doxorubicin—prostate cancer	2.71e-05	0.000138	CcSEcCtD
Doxepin—Gastrointestinal pain—Prednisone—prostate cancer	2.71e-05	0.000138	CcSEcCtD
Doxepin—Arthralgia—Epirubicin—prostate cancer	2.7e-05	0.000137	CcSEcCtD
Doxepin—Myalgia—Epirubicin—prostate cancer	2.7e-05	0.000137	CcSEcCtD
Doxepin—Chest pain—Epirubicin—prostate cancer	2.7e-05	0.000137	CcSEcCtD
Doxepin—Agitation—Doxorubicin—prostate cancer	2.7e-05	0.000137	CcSEcCtD
Doxepin—Anxiety—Epirubicin—prostate cancer	2.69e-05	0.000137	CcSEcCtD
Doxepin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	2.68e-05	0.000136	CcSEcCtD
Doxepin—Discomfort—Epirubicin—prostate cancer	2.67e-05	0.000136	CcSEcCtD
Doxepin—Asthenia—Capecitabine—prostate cancer	2.66e-05	0.000136	CcSEcCtD
Doxepin—Malaise—Doxorubicin—prostate cancer	2.65e-05	0.000135	CcSEcCtD
Doxepin—Dry mouth—Epirubicin—prostate cancer	2.64e-05	0.000134	CcSEcCtD
Doxepin—Vertigo—Doxorubicin—prostate cancer	2.64e-05	0.000134	CcSEcCtD
Doxepin—Syncope—Doxorubicin—prostate cancer	2.63e-05	0.000134	CcSEcCtD
Doxepin—Urticaria—Prednisone—prostate cancer	2.63e-05	0.000134	CcSEcCtD
Doxepin—Pruritus—Capecitabine—prostate cancer	2.63e-05	0.000134	CcSEcCtD
Doxepin—Leukopenia—Doxorubicin—prostate cancer	2.63e-05	0.000134	CcSEcCtD
Doxepin—Diarrhoea—Docetaxel—prostate cancer	2.62e-05	0.000133	CcSEcCtD
Doxepin—Abdominal pain—Prednisone—prostate cancer	2.62e-05	0.000133	CcSEcCtD
Doxepin—Body temperature increased—Prednisone—prostate cancer	2.62e-05	0.000133	CcSEcCtD
Doxepin—Confusional state—Epirubicin—prostate cancer	2.61e-05	0.000133	CcSEcCtD
Doxepin—Palpitations—Doxorubicin—prostate cancer	2.59e-05	0.000132	CcSEcCtD
Doxepin—Oedema—Epirubicin—prostate cancer	2.59e-05	0.000132	CcSEcCtD
Doxepin—Loss of consciousness—Doxorubicin—prostate cancer	2.58e-05	0.000131	CcSEcCtD
Doxepin—Infection—Epirubicin—prostate cancer	2.57e-05	0.000131	CcSEcCtD
Doxepin—Cough—Doxorubicin—prostate cancer	2.56e-05	0.00013	CcSEcCtD
Doxepin—Shock—Epirubicin—prostate cancer	2.55e-05	0.000129	CcSEcCtD
Doxepin—Convulsion—Doxorubicin—prostate cancer	2.54e-05	0.000129	CcSEcCtD
Doxepin—Diarrhoea—Capecitabine—prostate cancer	2.54e-05	0.000129	CcSEcCtD
Doxepin—Nervous system disorder—Epirubicin—prostate cancer	2.54e-05	0.000129	CcSEcCtD
Doxepin—Dizziness—Docetaxel—prostate cancer	2.54e-05	0.000129	CcSEcCtD
Doxepin—Thrombocytopenia—Epirubicin—prostate cancer	2.53e-05	0.000129	CcSEcCtD
Doxepin—Hypertension—Doxorubicin—prostate cancer	2.53e-05	0.000129	CcSEcCtD
Doxepin—Tachycardia—Epirubicin—prostate cancer	2.53e-05	0.000128	CcSEcCtD
Doxepin—Skin disorder—Epirubicin—prostate cancer	2.51e-05	0.000128	CcSEcCtD
Doxepin—Hyperhidrosis—Epirubicin—prostate cancer	2.5e-05	0.000127	CcSEcCtD
Doxepin—Chest pain—Doxorubicin—prostate cancer	2.5e-05	0.000127	CcSEcCtD
Doxepin—Myalgia—Doxorubicin—prostate cancer	2.5e-05	0.000127	CcSEcCtD
Doxepin—Arthralgia—Doxorubicin—prostate cancer	2.5e-05	0.000127	CcSEcCtD
Doxepin—Anxiety—Doxorubicin—prostate cancer	2.49e-05	0.000127	CcSEcCtD
Doxepin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	2.48e-05	0.000126	CcSEcCtD
Doxepin—Discomfort—Doxorubicin—prostate cancer	2.47e-05	0.000125	CcSEcCtD
Doxepin—Anorexia—Epirubicin—prostate cancer	2.47e-05	0.000125	CcSEcCtD
Doxepin—Dizziness—Capecitabine—prostate cancer	2.46e-05	0.000125	CcSEcCtD
Doxepin—Dry mouth—Doxorubicin—prostate cancer	2.44e-05	0.000124	CcSEcCtD
Doxepin—Vomiting—Docetaxel—prostate cancer	2.44e-05	0.000124	CcSEcCtD
Doxepin—Hypersensitivity—Prednisone—prostate cancer	2.44e-05	0.000124	CcSEcCtD
Doxepin—Rash—Docetaxel—prostate cancer	2.42e-05	0.000123	CcSEcCtD
Doxepin—Hypotension—Epirubicin—prostate cancer	2.42e-05	0.000123	CcSEcCtD
Doxepin—Dermatitis—Docetaxel—prostate cancer	2.42e-05	0.000123	CcSEcCtD
Doxepin—Confusional state—Doxorubicin—prostate cancer	2.41e-05	0.000123	CcSEcCtD
Doxepin—Headache—Docetaxel—prostate cancer	2.4e-05	0.000122	CcSEcCtD
Doxepin—Oedema—Doxorubicin—prostate cancer	2.39e-05	0.000122	CcSEcCtD
Doxepin—Infection—Doxorubicin—prostate cancer	2.38e-05	0.000121	CcSEcCtD
Doxepin—Asthenia—Prednisone—prostate cancer	2.37e-05	0.000121	CcSEcCtD
Doxepin—Vomiting—Capecitabine—prostate cancer	2.36e-05	0.00012	CcSEcCtD
Doxepin—Musculoskeletal discomfort—Epirubicin—prostate cancer	2.36e-05	0.00012	CcSEcCtD
Doxepin—Shock—Doxorubicin—prostate cancer	2.36e-05	0.00012	CcSEcCtD
Doxepin—Nervous system disorder—Doxorubicin—prostate cancer	2.35e-05	0.000119	CcSEcCtD
Doxepin—Thrombocytopenia—Doxorubicin—prostate cancer	2.34e-05	0.000119	CcSEcCtD
Doxepin—Rash—Capecitabine—prostate cancer	2.34e-05	0.000119	CcSEcCtD
Doxepin—Pruritus—Prednisone—prostate cancer	2.34e-05	0.000119	CcSEcCtD
Doxepin—Insomnia—Epirubicin—prostate cancer	2.34e-05	0.000119	CcSEcCtD
Doxepin—Dermatitis—Capecitabine—prostate cancer	2.34e-05	0.000119	CcSEcCtD
Doxepin—Tachycardia—Doxorubicin—prostate cancer	2.34e-05	0.000119	CcSEcCtD
Doxepin—Headache—Capecitabine—prostate cancer	2.33e-05	0.000118	CcSEcCtD
Doxepin—Skin disorder—Doxorubicin—prostate cancer	2.33e-05	0.000118	CcSEcCtD
Doxepin—Paraesthesia—Epirubicin—prostate cancer	2.32e-05	0.000118	CcSEcCtD
Doxepin—Hyperhidrosis—Doxorubicin—prostate cancer	2.31e-05	0.000118	CcSEcCtD
Doxepin—Dyspnoea—Epirubicin—prostate cancer	2.31e-05	0.000117	CcSEcCtD
Doxepin—Somnolence—Epirubicin—prostate cancer	2.3e-05	0.000117	CcSEcCtD
Doxepin—Anorexia—Doxorubicin—prostate cancer	2.28e-05	0.000116	CcSEcCtD
Doxepin—Nausea—Docetaxel—prostate cancer	2.28e-05	0.000116	CcSEcCtD
Doxepin—Dyspepsia—Epirubicin—prostate cancer	2.28e-05	0.000116	CcSEcCtD
Doxepin—Diarrhoea—Prednisone—prostate cancer	2.26e-05	0.000115	CcSEcCtD
Doxepin—Decreased appetite—Epirubicin—prostate cancer	2.25e-05	0.000114	CcSEcCtD
Doxepin—Hypotension—Doxorubicin—prostate cancer	2.24e-05	0.000114	CcSEcCtD
Doxepin—Gastrointestinal disorder—Epirubicin—prostate cancer	2.23e-05	0.000114	CcSEcCtD
Doxepin—Fatigue—Epirubicin—prostate cancer	2.23e-05	0.000113	CcSEcCtD
Doxepin—Constipation—Epirubicin—prostate cancer	2.21e-05	0.000113	CcSEcCtD
Doxepin—Pain—Epirubicin—prostate cancer	2.21e-05	0.000113	CcSEcCtD
Doxepin—Nausea—Capecitabine—prostate cancer	2.21e-05	0.000112	CcSEcCtD
Doxepin—Dizziness—Prednisone—prostate cancer	2.19e-05	0.000111	CcSEcCtD
Doxepin—Musculoskeletal discomfort—Doxorubicin—prostate cancer	2.18e-05	0.000111	CcSEcCtD
Doxepin—Insomnia—Doxorubicin—prostate cancer	2.17e-05	0.00011	CcSEcCtD
Doxepin—Paraesthesia—Doxorubicin—prostate cancer	2.15e-05	0.000109	CcSEcCtD
Doxepin—Dyspnoea—Doxorubicin—prostate cancer	2.13e-05	0.000109	CcSEcCtD
Doxepin—Feeling abnormal—Epirubicin—prostate cancer	2.13e-05	0.000108	CcSEcCtD
Doxepin—Somnolence—Doxorubicin—prostate cancer	2.13e-05	0.000108	CcSEcCtD
Doxepin—Gastrointestinal pain—Epirubicin—prostate cancer	2.12e-05	0.000108	CcSEcCtD
Doxepin—Dyspepsia—Doxorubicin—prostate cancer	2.11e-05	0.000107	CcSEcCtD
Doxepin—Vomiting—Prednisone—prostate cancer	2.1e-05	0.000107	CcSEcCtD
Doxepin—Rash—Prednisone—prostate cancer	2.09e-05	0.000106	CcSEcCtD
Doxepin—Dermatitis—Prednisone—prostate cancer	2.08e-05	0.000106	CcSEcCtD
Doxepin—Decreased appetite—Doxorubicin—prostate cancer	2.08e-05	0.000106	CcSEcCtD
Doxepin—Headache—Prednisone—prostate cancer	2.07e-05	0.000105	CcSEcCtD
Doxepin—Gastrointestinal disorder—Doxorubicin—prostate cancer	2.07e-05	0.000105	CcSEcCtD
Doxepin—Fatigue—Doxorubicin—prostate cancer	2.06e-05	0.000105	CcSEcCtD
Doxepin—Urticaria—Epirubicin—prostate cancer	2.06e-05	0.000105	CcSEcCtD
Doxepin—Pain—Doxorubicin—prostate cancer	2.05e-05	0.000104	CcSEcCtD
Doxepin—Constipation—Doxorubicin—prostate cancer	2.05e-05	0.000104	CcSEcCtD
Doxepin—Body temperature increased—Epirubicin—prostate cancer	2.05e-05	0.000104	CcSEcCtD
Doxepin—Abdominal pain—Epirubicin—prostate cancer	2.05e-05	0.000104	CcSEcCtD
Doxepin—Feeling abnormal—Doxorubicin—prostate cancer	1.97e-05	0.0001	CcSEcCtD
Doxepin—Nausea—Prednisone—prostate cancer	1.97e-05	9.99e-05	CcSEcCtD
Doxepin—Gastrointestinal pain—Doxorubicin—prostate cancer	1.96e-05	9.96e-05	CcSEcCtD
Doxepin—Hypersensitivity—Epirubicin—prostate cancer	1.91e-05	9.7e-05	CcSEcCtD
Doxepin—Urticaria—Doxorubicin—prostate cancer	1.9e-05	9.67e-05	CcSEcCtD
Doxepin—Body temperature increased—Doxorubicin—prostate cancer	1.89e-05	9.63e-05	CcSEcCtD
Doxepin—Abdominal pain—Doxorubicin—prostate cancer	1.89e-05	9.63e-05	CcSEcCtD
Doxepin—Asthenia—Epirubicin—prostate cancer	1.86e-05	9.44e-05	CcSEcCtD
Doxepin—Pruritus—Epirubicin—prostate cancer	1.83e-05	9.31e-05	CcSEcCtD
Doxepin—Diarrhoea—Epirubicin—prostate cancer	1.77e-05	9e-05	CcSEcCtD
Doxepin—Hypersensitivity—Doxorubicin—prostate cancer	1.76e-05	8.97e-05	CcSEcCtD
Doxepin—Asthenia—Doxorubicin—prostate cancer	1.72e-05	8.74e-05	CcSEcCtD
Doxepin—Dizziness—Epirubicin—prostate cancer	1.71e-05	8.7e-05	CcSEcCtD
Doxepin—Pruritus—Doxorubicin—prostate cancer	1.69e-05	8.61e-05	CcSEcCtD
Doxepin—Vomiting—Epirubicin—prostate cancer	1.65e-05	8.37e-05	CcSEcCtD
Doxepin—Diarrhoea—Doxorubicin—prostate cancer	1.64e-05	8.33e-05	CcSEcCtD
Doxepin—Rash—Epirubicin—prostate cancer	1.63e-05	8.3e-05	CcSEcCtD
Doxepin—Dermatitis—Epirubicin—prostate cancer	1.63e-05	8.29e-05	CcSEcCtD
Doxepin—Headache—Epirubicin—prostate cancer	1.62e-05	8.24e-05	CcSEcCtD
Doxepin—Dizziness—Doxorubicin—prostate cancer	1.58e-05	8.05e-05	CcSEcCtD
Doxepin—Nausea—Epirubicin—prostate cancer	1.54e-05	7.82e-05	CcSEcCtD
Doxepin—Vomiting—Doxorubicin—prostate cancer	1.52e-05	7.74e-05	CcSEcCtD
Doxepin—Rash—Doxorubicin—prostate cancer	1.51e-05	7.68e-05	CcSEcCtD
Doxepin—Dermatitis—Doxorubicin—prostate cancer	1.51e-05	7.67e-05	CcSEcCtD
Doxepin—Headache—Doxorubicin—prostate cancer	1.5e-05	7.63e-05	CcSEcCtD
Doxepin—Nausea—Doxorubicin—prostate cancer	1.42e-05	7.23e-05	CcSEcCtD
Doxepin—CHRM5—Signaling Pathways—PIK3CA—prostate cancer	1.11e-06	9.46e-06	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—MYC—prostate cancer	1.11e-06	9.46e-06	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—CAV1—prostate cancer	1.11e-06	9.46e-06	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—VEGFA—prostate cancer	1.11e-06	9.45e-06	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—PTEN—prostate cancer	1.11e-06	9.44e-06	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—TGFB1—prostate cancer	1.11e-06	9.44e-06	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—CDKN1A—prostate cancer	1.11e-06	9.44e-06	CbGpPWpGaD
Doxepin—CYP2D6—Metabolism—CREBBP—prostate cancer	1.1e-06	9.43e-06	CbGpPWpGaD
Doxepin—DRD2—Signaling by GPCR—AKT1—prostate cancer	1.1e-06	9.41e-06	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—PTEN—prostate cancer	1.1e-06	9.41e-06	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—CDKN1B—prostate cancer	1.1e-06	9.38e-06	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—MMP9—prostate cancer	1.1e-06	9.38e-06	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—STAT3—prostate cancer	1.1e-06	9.36e-06	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—MMP9—prostate cancer	1.1e-06	9.35e-06	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism—CREBBP—prostate cancer	1.09e-06	9.34e-06	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—CDKN1A—prostate cancer	1.09e-06	9.34e-06	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—PTEN—prostate cancer	1.09e-06	9.32e-06	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—CDKN1A—prostate cancer	1.09e-06	9.32e-06	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—PTEN—prostate cancer	1.09e-06	9.3e-06	CbGpPWpGaD
Doxepin—ADRA2A—GPCR downstream signaling—AKT1—prostate cancer	1.09e-06	9.28e-06	CbGpPWpGaD
Doxepin—HTR6—Signaling Pathways—IL6—prostate cancer	1.09e-06	9.27e-06	CbGpPWpGaD
Doxepin—HTR2A—Signaling by GPCR—AKT1—prostate cancer	1.09e-06	9.26e-06	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—EGFR—prostate cancer	1.08e-06	9.25e-06	CbGpPWpGaD
Doxepin—HTR2B—Signaling Pathways—TP53—prostate cancer	1.08e-06	9.25e-06	CbGpPWpGaD
Doxepin—HRH1—Signaling by GPCR—AKT1—prostate cancer	1.08e-06	9.24e-06	CbGpPWpGaD
Doxepin—CHRM1—Signaling by GPCR—AKT1—prostate cancer	1.08e-06	9.21e-06	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—EP300—prostate cancer	1.08e-06	9.2e-06	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—CASP3—prostate cancer	1.08e-06	9.19e-06	CbGpPWpGaD
Doxepin—CHRM3—Signaling by GPCR—AKT1—prostate cancer	1.08e-06	9.18e-06	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—IL2—prostate cancer	1.08e-06	9.18e-06	CbGpPWpGaD
Doxepin—CYP2C19—Metabolism—NOS3—prostate cancer	1.08e-06	9.18e-06	CbGpPWpGaD
Doxepin—CHRM5—Signaling Pathways—TP53—prostate cancer	1.07e-06	9.15e-06	CbGpPWpGaD
Doxepin—ADRA2A—Signaling by GPCR—IL6—prostate cancer	1.07e-06	9.13e-06	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—MYC—prostate cancer	1.07e-06	9.13e-06	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—TGFB1—prostate cancer	1.07e-06	9.11e-06	CbGpPWpGaD
Doxepin—CHRM2—Signaling by GPCR—AKT1—prostate cancer	1.07e-06	9.09e-06	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—MYC—prostate cancer	1.06e-06	9.09e-06	CbGpPWpGaD
Doxepin—ADRA1A—Signaling by GPCR—AKT1—prostate cancer	1.06e-06	9.07e-06	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—TGFB1—prostate cancer	1.06e-06	9.06e-06	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—TYMS—prostate cancer	1.06e-06	9.06e-06	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—EP300—prostate cancer	1.06e-06	9.05e-06	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—EP300—prostate cancer	1.06e-06	9.04e-06	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.06e-06	9.03e-06	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—EP300—prostate cancer	1.06e-06	9.01e-06	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—EP300—prostate cancer	1.05e-06	8.98e-06	CbGpPWpGaD
Doxepin—ADRA2C—Metabolism—PIK3CA—prostate cancer	1.05e-06	8.97e-06	CbGpPWpGaD
Doxepin—ABCB1—Metabolism—NOS3—prostate cancer	1.05e-06	8.96e-06	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—GSTM1—prostate cancer	1.05e-06	8.95e-06	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—CCND1—prostate cancer	1.05e-06	8.95e-06	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—SRC—prostate cancer	1.05e-06	8.95e-06	CbGpPWpGaD
Doxepin—CYP2D6—Metabolism—PIK3CD—prostate cancer	1.05e-06	8.94e-06	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—EGFR—prostate cancer	1.05e-06	8.93e-06	CbGpPWpGaD
Doxepin—ADRA1D—Signaling Pathways—PIK3CA—prostate cancer	1.04e-06	8.9e-06	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—EP300—prostate cancer	1.04e-06	8.89e-06	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—EGFR—prostate cancer	1.04e-06	8.89e-06	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—EP300—prostate cancer	1.04e-06	8.87e-06	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—CTNNB1—prostate cancer	1.04e-06	8.86e-06	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism—PIK3CD—prostate cancer	1.04e-06	8.86e-06	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—MYC—prostate cancer	1.04e-06	8.84e-06	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—TGFB1—prostate cancer	1.03e-06	8.82e-06	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—SRC—prostate cancer	1.03e-06	8.81e-06	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—LPL—prostate cancer	1.03e-06	8.79e-06	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—SRC—prostate cancer	1.03e-06	8.79e-06	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—SRC—prostate cancer	1.03e-06	8.76e-06	CbGpPWpGaD
Doxepin—CHRM4—Signaling Pathways—IL6—prostate cancer	1.03e-06	8.75e-06	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—KRAS—prostate cancer	1.02e-06	8.74e-06	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—SRC—prostate cancer	1.02e-06	8.73e-06	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—VEGFA—prostate cancer	1.02e-06	8.72e-06	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—MYC—prostate cancer	1.02e-06	8.7e-06	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—MMP9—prostate cancer	1.02e-06	8.69e-06	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—TGFB1—prostate cancer	1.02e-06	8.68e-06	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—CDKN1A—prostate cancer	1.01e-06	8.66e-06	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—SRC—prostate cancer	1.01e-06	8.65e-06	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—EGFR—prostate cancer	1.01e-06	8.64e-06	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—PTEN—prostate cancer	1.01e-06	8.64e-06	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—STAT3—prostate cancer	1.01e-06	8.63e-06	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—SRC—prostate cancer	1.01e-06	8.62e-06	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—PIK3CG—prostate cancer	1.01e-06	8.61e-06	CbGpPWpGaD
Doxepin—ADRA1D—Signaling Pathways—TP53—prostate cancer	1.01e-06	8.61e-06	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—VEGFA—prostate cancer	1e-06	8.58e-06	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—VEGFA—prostate cancer	1e-06	8.56e-06	CbGpPWpGaD
Doxepin—HTR6—Signaling Pathways—AKT1—prostate cancer	1e-06	8.56e-06	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—VEGFA—prostate cancer	1e-06	8.53e-06	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—EGFR—prostate cancer	9.97e-07	8.51e-06	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—VEGFA—prostate cancer	9.96e-07	8.5e-06	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—STAT3—prostate cancer	9.95e-07	8.49e-06	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—CYP1A1—prostate cancer	9.94e-07	8.49e-06	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—STAT3—prostate cancer	9.93e-07	8.47e-06	CbGpPWpGaD
Doxepin—CYP2C19—Metabolism—PIK3CB—prostate cancer	9.92e-07	8.47e-06	CbGpPWpGaD
Doxepin—HTR2B—Signaling Pathways—IL6—prostate cancer	9.92e-07	8.47e-06	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—STAT3—prostate cancer	9.9e-07	8.45e-06	CbGpPWpGaD
Doxepin—CYP2D6—Metabolism—NOS3—prostate cancer	9.89e-07	8.44e-06	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—KRAS—prostate cancer	9.89e-07	8.44e-06	CbGpPWpGaD
Doxepin—ADRA2A—Signaling by GPCR—AKT1—prostate cancer	9.87e-07	8.43e-06	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—VEGFA—prostate cancer	9.87e-07	8.42e-06	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—STAT3—prostate cancer	9.87e-07	8.42e-06	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—ERCC2—prostate cancer	9.86e-07	8.42e-06	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—VEGFA—prostate cancer	9.84e-07	8.4e-06	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—KRAS—prostate cancer	9.84e-07	8.4e-06	CbGpPWpGaD
Doxepin—CYP2C19—Metabolism—PTGS2—prostate cancer	9.83e-07	8.39e-06	CbGpPWpGaD
Doxepin—CHRM5—Signaling Pathways—IL6—prostate cancer	9.82e-07	8.38e-06	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism—NOS3—prostate cancer	9.8e-07	8.37e-06	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—STAT3—prostate cancer	9.77e-07	8.34e-06	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—STAT3—prostate cancer	9.74e-07	8.31e-06	CbGpPWpGaD
Doxepin—ABCB1—Metabolism—PIK3CB—prostate cancer	9.69e-07	8.27e-06	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—EP300—prostate cancer	9.65e-07	8.24e-06	CbGpPWpGaD
Doxepin—ABCB1—Metabolism—PTGS2—prostate cancer	9.6e-07	8.19e-06	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—KRAS—prostate cancer	9.57e-07	8.17e-06	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—INS—prostate cancer	9.55e-07	8.15e-06	CbGpPWpGaD
Doxepin—CHRM4—Signaling Pathways—AKT1—prostate cancer	9.46e-07	8.07e-06	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—KRAS—prostate cancer	9.42e-07	8.04e-06	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—PIK3CA—prostate cancer	9.41e-07	8.03e-06	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—MYC—prostate cancer	9.4e-07	8.02e-06	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—SRC—prostate cancer	9.39e-07	8.01e-06	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—TGFB1—prostate cancer	9.37e-07	8e-06	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—CREBBP—prostate cancer	9.36e-07	7.99e-06	CbGpPWpGaD
Doxepin—CHRM3—Metabolism—PIK3CA—prostate cancer	9.31e-07	7.94e-06	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—MTHFR—prostate cancer	9.27e-07	7.91e-06	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—MYC—prostate cancer	9.25e-07	7.89e-06	CbGpPWpGaD
Doxepin—ADRA1D—Signaling Pathways—IL6—prostate cancer	9.23e-07	7.88e-06	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—MYC—prostate cancer	9.23e-07	7.87e-06	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—TGFB1—prostate cancer	9.22e-07	7.87e-06	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—TGFB1—prostate cancer	9.2e-07	7.85e-06	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—MYC—prostate cancer	9.2e-07	7.85e-06	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—EGFR—prostate cancer	9.19e-07	7.84e-06	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—TGFB1—prostate cancer	9.17e-07	7.83e-06	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—MYC—prostate cancer	9.17e-07	7.82e-06	CbGpPWpGaD
Doxepin—HTR2B—Signaling Pathways—AKT1—prostate cancer	9.15e-07	7.81e-06	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—TGFB1—prostate cancer	9.14e-07	7.8e-06	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—VEGFA—prostate cancer	9.14e-07	7.8e-06	CbGpPWpGaD
Doxepin—CYP2D6—Metabolism—PIK3CB—prostate cancer	9.13e-07	7.79e-06	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—TP53—prostate cancer	9.1e-07	7.77e-06	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—PPARA—prostate cancer	9.09e-07	7.76e-06	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—PIK3CA—prostate cancer	9.09e-07	7.75e-06	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—MYC—prostate cancer	9.08e-07	7.75e-06	CbGpPWpGaD
Doxepin—CHRM5—Signaling Pathways—AKT1—prostate cancer	9.06e-07	7.73e-06	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—TGFB1—prostate cancer	9.06e-07	7.73e-06	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—MYC—prostate cancer	9.05e-07	7.73e-06	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—STAT3—prostate cancer	9.05e-07	7.73e-06	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism—PIK3CB—prostate cancer	9.05e-07	7.72e-06	CbGpPWpGaD
Doxepin—CYP2D6—Metabolism—PTGS2—prostate cancer	9.04e-07	7.72e-06	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—EGFR—prostate cancer	9.04e-07	7.72e-06	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—PIK3CA—prostate cancer	9.04e-07	7.71e-06	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—TGFB1—prostate cancer	9.03e-07	7.71e-06	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—EGFR—prostate cancer	9.02e-07	7.7e-06	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—EGFR—prostate cancer	8.99e-07	7.68e-06	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism—PTGS2—prostate cancer	8.97e-07	7.65e-06	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—EGFR—prostate cancer	8.97e-07	7.65e-06	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—EGFR—prostate cancer	8.88e-07	7.58e-06	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—PIK3CD—prostate cancer	8.87e-07	7.57e-06	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—EGFR—prostate cancer	8.85e-07	7.56e-06	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—PIK3CA—prostate cancer	8.79e-07	7.5e-06	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—TP53—prostate cancer	8.79e-07	7.5e-06	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—TP53—prostate cancer	8.74e-07	7.46e-06	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—KRAS—prostate cancer	8.68e-07	7.41e-06	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—PIK3CA—prostate cancer	8.65e-07	7.38e-06	CbGpPWpGaD
Doxepin—ADRA2C—Metabolism—AKT1—prostate cancer	8.59e-07	7.33e-06	CbGpPWpGaD
Doxepin—CYP2C19—Metabolism—PTEN—prostate cancer	8.58e-07	7.32e-06	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—CAV1—prostate cancer	8.55e-07	7.3e-06	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—KRAS—prostate cancer	8.54e-07	7.29e-06	CbGpPWpGaD
Doxepin—ADRA2A—Metabolism—PIK3CA—prostate cancer	8.54e-07	7.29e-06	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—KRAS—prostate cancer	8.52e-07	7.27e-06	CbGpPWpGaD
Doxepin—ADRA1D—Signaling Pathways—AKT1—prostate cancer	8.52e-07	7.27e-06	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—TP53—prostate cancer	8.5e-07	7.26e-06	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—KRAS—prostate cancer	8.5e-07	7.25e-06	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—KRAS—prostate cancer	8.47e-07	7.23e-06	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—MYC—prostate cancer	8.41e-07	7.18e-06	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—TGFB1—prostate cancer	8.39e-07	7.16e-06	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—KRAS—prostate cancer	8.39e-07	7.16e-06	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—NOS3—prostate cancer	8.38e-07	7.15e-06	CbGpPWpGaD
Doxepin—ABCB1—Metabolism—PTEN—prostate cancer	8.37e-07	7.14e-06	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—TP53—prostate cancer	8.37e-07	7.14e-06	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—KRAS—prostate cancer	8.36e-07	7.14e-06	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—IL6—prostate cancer	8.33e-07	7.11e-06	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—EGFR—prostate cancer	8.23e-07	7.02e-06	CbGpPWpGaD
Doxepin—CYP2C19—Metabolism—EP300—prostate cancer	8.18e-07	6.98e-06	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—IL6—prostate cancer	8.04e-07	6.87e-06	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—IL6—prostate cancer	8e-07	6.83e-06	CbGpPWpGaD
Doxepin—ABCB1—Metabolism—EP300—prostate cancer	7.98e-07	6.81e-06	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—PIK3CA—prostate cancer	7.98e-07	6.81e-06	CbGpPWpGaD
Doxepin—CYP2D6—Metabolism—PTEN—prostate cancer	7.89e-07	6.73e-06	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—PIK3CA—prostate cancer	7.85e-07	6.7e-06	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—PIK3CA—prostate cancer	7.83e-07	6.68e-06	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism—PTEN—prostate cancer	7.82e-07	6.67e-06	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—PIK3CA—prostate cancer	7.81e-07	6.66e-06	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—PIK3CG—prostate cancer	7.79e-07	6.65e-06	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—IL6—prostate cancer	7.78e-07	6.64e-06	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—PIK3CA—prostate cancer	7.78e-07	6.64e-06	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—KRAS—prostate cancer	7.77e-07	6.63e-06	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—PIK3CB—prostate cancer	7.73e-07	6.6e-06	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—TP53—prostate cancer	7.72e-07	6.59e-06	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—PIK3CA—prostate cancer	7.71e-07	6.58e-06	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—AKT1—prostate cancer	7.69e-07	6.56e-06	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—PIK3CA—prostate cancer	7.69e-07	6.56e-06	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—PTGS2—prostate cancer	7.66e-07	6.54e-06	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—IL6—prostate cancer	7.66e-07	6.54e-06	CbGpPWpGaD
Doxepin—CHRM3—Metabolism—AKT1—prostate cancer	7.6e-07	6.49e-06	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—TP53—prostate cancer	7.59e-07	6.48e-06	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—TP53—prostate cancer	7.58e-07	6.47e-06	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—TP53—prostate cancer	7.55e-07	6.45e-06	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—TP53—prostate cancer	7.53e-07	6.42e-06	CbGpPWpGaD
Doxepin—CYP2D6—Metabolism—EP300—prostate cancer	7.52e-07	6.42e-06	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism—EP300—prostate cancer	7.46e-07	6.36e-06	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—TP53—prostate cancer	7.46e-07	6.36e-06	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—TP53—prostate cancer	7.43e-07	6.34e-06	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—AKT1—prostate cancer	7.42e-07	6.33e-06	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—AKT1—prostate cancer	7.38e-07	6.3e-06	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—INS—prostate cancer	7.37e-07	6.29e-06	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—CREBBP—prostate cancer	7.22e-07	6.16e-06	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—AKT1—prostate cancer	7.18e-07	6.13e-06	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—PIK3CA—prostate cancer	7.14e-07	6.09e-06	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—AKT1—prostate cancer	7.07e-07	6.03e-06	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—IL6—prostate cancer	7.06e-07	6.03e-06	CbGpPWpGaD
Doxepin—ADRA2A—Metabolism—AKT1—prostate cancer	6.98e-07	5.95e-06	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—IL6—prostate cancer	6.95e-07	5.93e-06	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—IL6—prostate cancer	6.94e-07	5.92e-06	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—IL6—prostate cancer	6.91e-07	5.9e-06	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—TP53—prostate cancer	6.91e-07	5.9e-06	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—IL6—prostate cancer	6.89e-07	5.88e-06	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—PIK3CD—prostate cancer	6.85e-07	5.84e-06	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—IL6—prostate cancer	6.82e-07	5.82e-06	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—IL6—prostate cancer	6.81e-07	5.81e-06	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—PTEN—prostate cancer	6.68e-07	5.7e-06	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—AKT1—prostate cancer	6.52e-07	5.56e-06	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—NOS3—prostate cancer	6.47e-07	5.52e-06	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—AKT1—prostate cancer	6.41e-07	5.47e-06	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—AKT1—prostate cancer	6.4e-07	5.46e-06	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—AKT1—prostate cancer	6.38e-07	5.44e-06	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—EP300—prostate cancer	6.37e-07	5.44e-06	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—AKT1—prostate cancer	6.36e-07	5.43e-06	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—IL6—prostate cancer	6.32e-07	5.4e-06	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—AKT1—prostate cancer	6.3e-07	5.37e-06	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—AKT1—prostate cancer	6.28e-07	5.36e-06	CbGpPWpGaD
Doxepin—CYP2C19—Metabolism—PIK3CA—prostate cancer	6.05e-07	5.16e-06	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—PIK3CB—prostate cancer	5.97e-07	5.09e-06	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—PTGS2—prostate cancer	5.91e-07	5.05e-06	CbGpPWpGaD
Doxepin—ABCB1—Metabolism—PIK3CA—prostate cancer	5.91e-07	5.04e-06	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—AKT1—prostate cancer	5.83e-07	4.98e-06	CbGpPWpGaD
Doxepin—CYP2D6—Metabolism—PIK3CA—prostate cancer	5.56e-07	4.75e-06	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism—PIK3CA—prostate cancer	5.52e-07	4.71e-06	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—PTEN—prostate cancer	5.16e-07	4.4e-06	CbGpPWpGaD
Doxepin—CYP2C19—Metabolism—AKT1—prostate cancer	4.94e-07	4.22e-06	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—EP300—prostate cancer	4.92e-07	4.2e-06	CbGpPWpGaD
Doxepin—ABCB1—Metabolism—AKT1—prostate cancer	4.82e-07	4.12e-06	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—PIK3CA—prostate cancer	4.71e-07	4.02e-06	CbGpPWpGaD
Doxepin—CYP2D6—Metabolism—AKT1—prostate cancer	4.55e-07	3.88e-06	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism—AKT1—prostate cancer	4.51e-07	3.85e-06	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—AKT1—prostate cancer	3.85e-07	3.29e-06	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—PIK3CA—prostate cancer	3.64e-07	3.1e-06	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—AKT1—prostate cancer	2.97e-07	2.54e-06	CbGpPWpGaD
